Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TKT | P29401 | 1/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25370967 | 0.76 | TKT (0.37) | TKTMEN1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3182502 | 0.75 | DHFR (0.43) | — | |
| SCHEMBL27089486 | 0.74 | TKT (0.43) | TKTCYP1A2KMT2A | |
| SCHEMBL29998587 | 0.74 | TKT (0.43) | TKTCYP1A2KMT2A | |
| SCHEMBL12877696 | 0.72 | — | — | |
| SCHEMBL29895017 | 0.72 | LMNA (0.51) | TKTCYP1A2 | |
| SCHEMBL1571451 | 0.72 | LMNA (0.51) | TKTCYP1A2 | |
| SCHEMBL11807834 | 0.70 | DHFR (0.36) | — | |
| SCHEMBL317516 | 0.70 | — | — | |
| SCHEMBL27655885 | 0.69 | TKT (0.39) | TKTMEN1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103896935-A | Preparation method for 3-[(4-amino-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methylthiazole nitrate | Jiangxi tianxin pharmaceutical co ltd | 2014-07-02 | — | — | CN | disclosed |
| US-8198443-B2 | Synthesis of 4-amino-pyrimidines scaffolds | DSM IP ASSETS B.V. (NL) | 2012-06-12 | — | — | US | disclosed |
| US-20100016591-A1 | SYNTHESIS OF 4-AMINO-PYRIMIDINES SCAFFOLDS | DSM IP ASSETS B.V. (NL) | 2010-01-21 | — | — | US | disclosed |
| EP-2102172-A1 | SYNTHESIS OF 4-AMINO-PYRIMIDINES | DSM IP Assets B.V. (NL) | 2009-09-23 | — | — | EP | disclosed |
| EP-1972620-A1 | Synthesis of 4-amino-pyrimidines | DSMIP Assets B.V. (NL) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008087021-A1 | SYNTHESIS OF 4-AMINO-PYRIMIDINES | DSM IP ASSETS B.V. (NL) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016591-A1 | SYNTHESIS OF 4-AMINO-PYRIMIDINES SCAFFOLDS | HRH3, HRH4, CBR3 | TKT 3186/4885ADH1B 2096/4885ADH1C 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.